Colorectal Cancer Biomarkers
Key Points
Key Points
Current evidence-based recommendations for the molecular testing of CRC tissues to guide EGFR-targeted therapies and conventional chemotherapy regimens were developed through collaboration of four societies: American Society for Clinical Pathology (ASCP), College of American Pathologists (CAP), Association for Molecular Pathology (AMP), and American Society of Clinical Oncology (ASCO).
Diagnosis
Diagnosi...
...inoma patients being considered for anti-E...
...AF p.V600 (BRAF c. 1799 (p.V600) mutat...
...mutational analysis should be performed...
...ld order mismatch repair status testing in patie...
...is insufficient evidence to recommend BRA...
...fficient evidence to recommend PIK3CA mutati...
...is insufficient evidence to recommend PTEN anal...
...c or recurrent colorectal carcinoma tissues a...
...n fixed paraffin embedded tissue is a...
...ies must use validated colorectal carcinoma m...
...f molecular biomarker testing for...
...boratories must validate the performanc...
...ories must provide clinically appro...
...and IHC biomarker testing in colorecta...
...ratories should establish policies...
...rs of the patient’s medical team,...
...aboratories that require send out of tests fo...
...ists must evaluate candidate specime...
...tories should use colorectal carcinoma...
...arcinoma molecular biomarker results shoul...
...rcinoma molecular biomarker testing reports...
...aboratories must incorporate colorectal carci...
...1. Outcomes of RAS Mutations and An...
.... Concordance Rates Between Primar...